Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study - 31/05/22

Doi : 10.1016/S1470-2045(22)00202-9

Lennard Y W Lee, DPhil ^a,^b,^{*
Joint first authors}⁎ , Thomas Starkey, MSci ^b,^{*
Joint first authors}, Maria C Ionescu, MSci ^e,^{*
Joint first authors}, Martin Little, MRes ^f,^{*
Joint first authors}, Michael Tilby, MBChB ^g,^{*
Joint first authors}, Arvind R Tripathy, MD ^g,^{*
Joint first authors}, Hayley S Mckenzie, PhD ^h,^{*
Joint first authors}, Youssra Al-Hajji ^d, Matthew Barnard, PhD ^e, Liza Benny, PhD ^e, Alexander Burnett, FRCR ^i,^j, Emma L Cattell, PhD ^k, Jackie Charman, BSc ^l, James J Clark, MBBChir ^m, Sam Khan, PhD ⁿ, Qamar Ghafoor, MBChB ^g, George Illsley, BSc ^e, Catherine Harper-Wynne, MD ^o, Rosie J Hattersley, MBChB ^p, Alvin J X Lee, PhD ^q, Pauline C Leonard, FRCP ^s, Justin K H Liu, MRCP ^t,
NCRI Consumer Forum
Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson

Matthew Pang, PhD ^u, Jennifer S Pascoe, MRCP ^g, James R Platt, MRes ^t, Vanessa A Potter, PhD ^v, Amelia Randle, MRCP ^w, Anne S Rigg, FRCP ^x, Tim M Robinson, PhD ^y, Tom W Roques, FRCR ^z, René L Roux, MRCP ^f, Stefan Rozmanowski, MMath ^u, Mark H Tuthill, PhD ^f, Isabella Watts, BMBCh ^aa, Sarah Williams, FRCP ^g, Tim Iveson, ProfMD ^ab, Siow Ming Lee, ProfFRCP ^q,^r, Gary Middleton, ProfFRCP ^c,^g, Mark Middleton, ProfPhD ^a, Andrew Protheroe, ProfMD ^f, Matthew W Fittall, PhD ^ac,^{^{†
Joint senior authors}}, Tom Fowler, PhD ^e,^{^{†
Joint senior authors}}, Peter Johnson, ProfMD ^i,^ab,^{^{†
Joint senior authors}}

^a Department of Oncology, University of Oxford, Oxford, UK

^b Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

^c Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

^d Birmingham Medical School, University of Birmingham, Birmingham, UK

^e UK Health Security Agency, London, UK

^f Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

^g Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

^h Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK

ⁱ NHS England, London, UK

^j NHS Improvement, London, UK

^k Department of Cancer, Taunton and Somerset NHS Foundation Trust, Taunton, UK

^l National Disease Registration Service, NHS Digital, London, UK

^m Department of Surgery and Cancer, Imperial College London, London, UK

ⁿ Leicester Cancer Research Centre, University of Leicester, Leicester, UK

^o Kent Oncology Centre, University of Kent and Kent and Medway Medical School, Maidstone, UK

^p Department of Oncology, Torbay Hospital NHS Foundation Trust, Torquay, UK

^q UCL Cancer Institute, University College London Hospitals NHS Trust and University College London, London, UK

^r CRUK Lung Cancer Centre of Excellence, University College London Hospitals NHS Trust and University College London, London, UK

^s Cancer Services, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK

^t Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK

^u Department of Health and Social Care, London, UK

^v Department of Oncology, University Hospital Coventry and Warwickshire, Coventry, UK

^w Royal College of Physicians, London, UK

^x Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

^y Population Health Sciences, University of Bristol, Bristol, UK

^z Cancer Services, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

^aa Department of Academic Oncology, Royal Free Hospital, London, UK

^ab Cancer Sciences, University of Southampton, Southampton, UK

^ac Cancer Services, The Royal Marsden NHS Foundation Trust, London, UK

^* Correspondence to: Dr Lennard Y W Lee, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK Department of Oncology University of Oxford Oxford OX3 7DQ UK

conectar o crear una cuenta

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Background

People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level.

Methods

In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England’s Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3–6 months after the second dose in the cancer cohort and control population.

Findings

The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8–69·9) in the control population and 65·5% (65·1–65·9) in the cancer cohort. Vaccine effectiveness at 3–6 months was lower in the cancer cohort (47·0%, 46·3–47·6) than in the control population (61·4%, 61·4–61·5).

Interpretation

COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer.

Funding

University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK.

El texto completo de este artículo está disponible en PDF.

Esquema

Introduction

Methods

Study design and data sources

Statistical analysis

Role of the funding source

Results

Discussion

Data sharing

Exportación

Vol 23 - N° 6

P. 748-757 - juin 2022 Regresar al número

Artículo precedente

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng, CAPSTONE-1 Study Group, Ying Cheng, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Huiqing Yu, Jian Zhao, Gang Wu, Dingzhi Huang, Chengshui Chen, Cuimin Ding, Baihong Zhang, Xiuwen Wang, Hui Luo, Baolan Li, Shucai Zhang, Hong Lu, Meiqi Shi, Xi Chen, Yubiao Guo, Hailong Liu, Jiwei Liu, Hongjun Gao, Sheng Hu, Qunying Hong, Qi Li, Ben Zhang, Wei Shi, Xiaojing Zhang

| Artículo siguiente

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Forster, Robert B Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R Michaud, Attila Szanto, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A Fennell

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

conectar o crear una cuenta

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study - 31/05/22

Summary

Background

Methods

Findings

Interpretation

Funding

Esquema

Exportación citas

Fichero

Contenido

Mi cuenta

Aide & support

Declaración CNIL